Navigation Links
Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
Date:9/11/2007

Generic Erosion of Zocor and Lipitor Will Cause Market Share of Statins to Drop Nearly 40% by 2016, According to a New Report from Decision Resources

WALTHAM, Mass., Sept. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the market entry of novel angiogenic agents, including a future blockbuster drug from Genzyme, could revolutionize symptomatic treatment of peripheral arterial disease (PAD).

The new Pharmacor report Peripheral Arterial Disease finds that Genzyme's HIF-1 alpha therapy for PAD patients with intermittent claudication, which could reach the market as early as 2010, will garner sales of $1.5 billion in 2016 in the world's major pharmaceutical markets. Experts are optimistic about the market entry of novel angiogenic therapies, which act by generating new blood vessels in the legs and are the first agents to be developed as disease- modifying therapies for PAD. Although numerous studies will be required to establish the efficacy and safety of angiogenic products, physicians are hopeful these pioneering, PAD-specific therapies will be effective in treating the intermittent claudication and critical limb ischemia patient segments.

The report also finds that although statins will continue to dominate the PAD prescription landscape, the U.S. patent expiries of Merck's Zocor in 2006 and Pfizer's Lipitor in 2010 will cause total statin market share to drop from 58% in 2006 to 21% in 2016. The U.S. patent expiry of Zocor will prompt a rapid and extensive shift in prescribing to generic equivalents from 2007 onward as third-party payers remove the brand from formularies.

"Patient-share growth will be fastest for generic Zocor, which will overtake Lipitor for prescriptions in the majority of newly diagnosed PAD patients who may be unable to afford the high co-payments associated with Lipitor," said Mary Argent-Katwala, Ph.D., analyst at
'/>"/>

SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
2. High-Fidelity PCR with a Novel Polymerase Mixture
3. Challenge the Performance of Your Hot-Start PCRs with FastStart Taq DNA Polymerase and the Novel FastStart High Fidelity PCR System
4. Combine High Yield, Great Accuracy and the Prevention of Carry-over Contamination by Using the Novel Expand High FidelityPLUS PCR System
5. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
6. A Novel Process for Gene Expression Profiling of Rat and Mouse Tissues from Formalin-Fixed Paraffin-Embedded Sections Using Microarrays
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
9. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Life-sciences conference to feature novel research with clinical potential

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ENNA, Austria, November 19 AFFiRiS...one product candidate at an unexpectedly early,sta...lanned to enter into,Phase II clinical trial early... follows the completion of two Phase I trials with...ts fast decision on the first interim,analysis of ...
(Date:11/18/2009)...Imagine a polka-dotted postage stamp that can snif...hanging colors. , As reported in the Sept. 13 is...lick and his team at the University of Illinois ha...tection of toxic industrial chemicals (TICs) that ...alizing odors. This sensor array could be useful ...
(Date:11/18/2009)...lif., Nov. 18 Masimo (...(TM) and Measure-Through Motion and Low-Perfusion ...based Uni.H.A., one of the largest healthcare Grou...gned a multi-year purchasing agreement for "gold s...agreement offers preferred contract pricing to Uni...
(Date:11/18/2009)... Promega Corporation and SwitchGear Genomics a...ein interactions. , Madis...orporation and SwitchGear Genomics announce a nove...ns. Results of a study using the HaloCHIP™ S...ate the ability to correlate DNA binding events to...
Breaking Biology Technology:AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4Promega and SwitchGear Publish Findings from Combined Technologies that Correlate Binding Events and Transcriptional Activity 2
...23 Boston Scientific,Corporation (NYSE: BSX ) to... $2 billion revolving line of credit and $5 billio...onal financial flexibility as it implements,initia... were pleased to work with our lenders to amend ou...Chief Executive Officer of Boston,Scientific. "The...
...23 Mirus Bio Corporation today,announced that it ... since,January of this year totaling $5.4 million....ng $2.4 million to further develop the Company...orm and alternative nanoparticle technologies,...ver applications; [Principal Investigat...
...Aug. 23 AspenBio Pharma,Inc. (OTC Bulletin Board:...cated to the development of novel drugs and diagno...application to list its common stock on the,NASDAQ... The company anticipates its shares of common sto...with the open of trading on Tuesday, August 28,200...
Other Biology Technology:Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan 2Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan 3Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan 4Mirus Bio Awarded Grants & Contracts of Over $5 Million 2AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 2AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 3AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol 'APPY' 4
(Date:11/19/2009)...ain chemical with an unwieldy name: 4-hydroxybutyr...ed as a date-rape drug. , Now, a team of Ohio a...by which 4-HB is metabolized by the body. "This is...ibson, professor and chair of biological sciences ...of the research team. "It may provide new clues o...
(Date:11/19/2009)...s are revealing the genetic instructions inside co...ize, has one of the most complex sequences of DNA ...n genomicist David Schwartz, who was one of more t...ence . , "The maize genome is a true maze full ...led would-be sequencers for years," says Schwartz....
(Date:11/19/2009)...four-year, multi-institutional effort co-led by th...s culminated today in publication of a landmark se...in unprecedented detail the DNA sequence of maize ...lled by North American consumers, is one of the wo...agricultural crop grown in the United States, repr...
Breaking Biology News(10 mins):Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Caraco Pharmaceutical Laboratories Ltd Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations 5070 1Caraco Pharmaceutical Laboratories Ltd Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations 5070 2Lupin Expands Branded Play 5066 1Lupin Expands Branded Play 5066 2Lupin Expands Branded Play 5066 3Despite size NFL players not more likely to develop heart disease even after retirement 58486 1Despite size NFL players not more likely to develop heart disease even after retirement 58486 2
...is release is available in French . , ,Saskatoo...y is good for you. But why exactly is it good for ...nd tissues of the body? What do we need to know so...y to combat chronic diseases such as arthritis, di...hological factors prevent people from exercising o...
...entary school students will eat more whole grains ...uced into their school lunches, a new University o... strongly recommended as part of a healthy diet, b...or this study, researchers from the university,s d...how much bread students threw away, and whether th...
... the Tour de France to NASCAR, competitors and fan...rategy -- and the ability to use elements like aer... closely behind a leader than to be out in front -... happens in reverse: It,s the leader of a pack who...ounter more resistance -- and have to expend more ...
Other Biology News:Physical activity and health: Finding the right prescription 2Following the leader can be a drag, according to student's research on flapping flags 2
...- 5 units/µL ,• High specific activit...ll; Leaves an 'A' overhang ,• Processes ...ry high activity in primer extension and other mol... of the enzyme, each lot has been functionally tes...
AmpliTaq DNA Polymerase with Buffer II from Applied Biosystems
...- 5 units/µL ,• High specific activit...ll; Leaves an 'A' overhang ,• Processes ,...y high activity in primer extension and other mole...of the enzyme, each lot has been functionally test...
AmpliTaq DNA Polymerase with Buffer I from Applied Biosystems
Biology Products: